GVR Report cover Peptide And Oligonucleotide CDMO Market Size, Share & Trends Report

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report by Services, by End User, by Region, And Segment Forecasts, 2023 To 2030

  • Report ID: GVR454141
  • Number of Pages: 0
  • Format: Electronic (PDF)

Industry Insights

The global peptide and oligonucleotide CDMO market is anticipated to reflect a considerable growth rate across the forecast period. Oligonucleotides are short RNA or DNA molecules. Whereas peptides are a chain of amino acids. These molecules are used in various therapeutic areas, including cancer, cardiological diseases, infectious diseases, diabetes, respiratory disorders, and others. The high burden of these disorders worldwide supports the demand for peptide oligonucleotide development and manufacturing activities and thus supports segment growth.

During the COVID-19 pandemic, most clinical research activities focused on developing and manufacturing drugs for treating COVID-19. However, in the post-pandemic period, clinical research activities primarily focused on biotech-related drug products such as peptides, nucleotides, oligonucleotides, and others. For instance, according to Pharma R&D Annual Review, Biotechnology related drugs accounted for the majority of the drugs in the pipeline in 2022. This is expected to support the market in the post-pandemic period..

Based on end user, peptide and oligonucleotide CDMO market is segmented into pharmaceutical companies,  biotech companies and others. The biotech companies segment has held a substantial share in the peptide and oligonucleotide CDMO market. A significant number of biotech companies are undergoing collaborations with peptides and oligonucleotides CDMOs. For instance, in December 2021, Wuxi STA collaborated with Coherent Biopharm. As per the agreement, Wuxi STA  provided Coherent Biopharm with CMC services to accelerate the development of peptides, oligonucleotides, complex chemical conjugates, and others. This is expected to support the segment market growth.

The Asia Pacific region is expected to grow with significant growth across the forecast. The presence of a substantial number of CDMOs in the region providing high-quality and cost-effective development and manufacturing services for peptides and oligonucleotides is a significant factor supporting the regional market growth of peptide and oligonucleotide CDMO market.

The key global industry players across the peptide and oligonucleotide CDMO market includes WuXi STA, Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, Curia Global, Inc., CordenPharm, Polypetide Group, ST Pharm Co.Ltd., Sylentis, S.A.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

ESOMAR Certified Member Great Place to Work Certified

ESOMAR & Great Work to Place Certified

ISO 9001:2015 & 27001:2022 Certified

ISO 9001:2015 & 27001:2022 Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.